2020 American Transplant Congress
Transplantation from Donors with Positive Blood Culture
Department of Surgery, Seoul National University Hospital, Seoul, Korea, Republic of
*Purpose: The use of organs from donors with infection is limited because of the possibility of transmission. Herein we report our experience of transplantation from…2020 American Transplant Congress
Real-World Experiences in the Transplantation of Hepatitis C Positive Kidneys
*Purpose: With advancements of direct-acting antivirals, transplantation of HCV-NAT+ (HCV+) organs to HCV-negative (HCV-) recipients has been used to decrease wait times without apparent sacrifice…2020 American Transplant Congress
Effect of Everolimus and Reduced Calcineurin Inhibitors on Biopsy Proven BK Virus Associated Nephropathy
Cleveland Clinic, Cleveland, OH
*Purpose: BK virus-associated nephropathy (BKVAN) is a clinically important entity that contributes to allograft loss in kidney transplant recipients (KTRs). Mammalian target of rapamycin inhibitors…2020 American Transplant Congress
Viral Kinetics of De Novo HCV Infection and Response to Antiviral Therapy in Liver and Kidney Transplant Recipients Receiving HCV-Viremic Donors
*Purpose: There is general agreement that expanded use of organs from HCV-viremic donors is desirable, including in recipients without HCV infection. However, the optimal treatment…2020 American Transplant Congress
Evaluation of Cytomegalovirus Prophylaxis in Low and Intermediate Risk Kidney Transplant Recipients Receiving Lymphocyte-Depleting Induction
Hartford Hospital, Hartford, CT
*Purpose: This study evaluates if choice and duration of Cytomegalovirus (CMV) prophylaxis based on donor (D) and recipient (R) CMV serostatus impacts the incidence of…2020 American Transplant Congress
BK Viremia: A Double Edged Sword – The Impact of Immunosuppression Reduction on Allograft Rejection
*Purpose: BK viremia (BKV) increases the risk of renal allograft loss following transplant. Guidelines recommend reduction of immunosuppression (IS) after BKV diagnosis, however, the ideal…2020 American Transplant Congress
Immune Checkpoint Inhibitor Use in Kidney Transplant Recipients: Rejection Risk, Prevention and Transcriptional Signature in Allograft
1Brigham and Women's Hospital, Boston, MA, 2University of Alberta, Edmonton, AB, Canada
*Purpose: Immune checkpoint inhibitor (ICI) use has changed the landscape of cancer treatment. Several cases of acute rejection in use of ICI have been reported,…2020 American Transplant Congress
Contrary to Expectation, the Use of Immune Checkpoint Inhibitors is Not Consistently Associated with Early Onset Allograft Rejection in Solid Organ Transplant Recipients
*Purpose: Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy but are generally avoided in solid organ transplant recipients (SOTRs) due to concern for allograft rejection…2020 American Transplant Congress
Comparative Analysis of Risk Factors and Outcomes in Kidney Transplant Recipients with Lung Cancer and Those with No Malignancy: UNOS Data Set
*Purpose: Transplant recipients are at increased risk for malignancy. Patients who develop cancer after transplant have worse outcomes, especially those with lung cancer. Transplant-related risk…2020 American Transplant Congress
Clinical Features and Transplant Outcomes in Kidney Transplant Recipients with Renal Cell Carcinoma
Asan Medical Center, Seoul, Korea, Republic of
*Purpose: Previous studies have recommended a 2-5-year waiting time prior to kidney transplantation (KT) in patients with end-stage renal disease (ESRD) and symptomatic renal cell…
- « Previous Page
- 1
- …
- 361
- 362
- 363
- 364
- 365
- …
- 1683
- Next Page »